Rod D. Martin is a technology entrepreneur, hedge fund manager and angel investor from Destin, Florida.
Either personally or through his fund he is an investor, director or officer of several ventures in the internet and biotech spaces, most recently including CapLinked, Advanced Search Laboratories and Proxomo. Following his wifeâ€™s successful bout with breast cancer, in 2009 he led the takeover and restructuring of Galectin Therapeutics, (formerly Pro-Pharmaceuticals), whose lead candidate drug, in clinical trials, has greatly enhanced the effectiveness of chemotherapy agents while nearly eliminating their side-effects, and whose second candidate promises to eliminate the need for liver and kidney transplants.
He previously served as Director of Policy Planning and Research for former Presidential candidate Mike Huckabee. He is a member of the Board of Governors of the Council for National Policy, a past chairman of The Arlington Groupâ€™s National Security Team, and also serves on numerous charitable foundation boards, including Hugh Oâ€™Brian Youth Leadership (HOBY). He studied 18th century political economy at Cambridge University and was elected student body president at Baylor Law School. A noted futurist and award-winning civil rights scholar, he is author of four books, including the forthcoming The Imperative of Excellence.